Thanks doc,
From your post, “Reverse stock splits don't affect the number of authorized shares, but a forward stock split issues new stock from the company's authorized shares.”
Speaking of Reverse and not Forward, when an R/S occurs and the authorized shares remain the same. What’s the math?
For instance, a 5 to 1 R/S.
We have about 800 million out. And 1.35 Billion authorized.
So theoretically, if our 800 million outstanding gets reversed, we end up with about 160 million outstanding, correct? At the same time, our shareholders authorized count remains at 1.35 billion.
IF we can sell all of those 1.2 billion remaining authorized shares at a X5 higher price than that would rock. The discussion I’m asking about is the in between part.
IF my example, (again, not saying it’s at all in the offing) is worthy of discussion, what might the engineering, timing, math, effect on my shares be? I’m hoping this guy both knows and has my best interest in mind.
“Stephen M. Simes
Director
Mr. Simes is an accomplished public company CEO who led a number of biopharmaceutical companies during his over 40 year career in the industry. He has extensive experience developing and implementing corporate strategies, establishing growth metrics, driving performance, and meeting growth objectives through organic expansion, acquisitions, and partnerships. When CEO at RestorGenex Corporation, Mr. Simes built a successful senior executive leadership team that delivered significant therapeutic products and stockholder value. He also negotiated the merger of RestorGenex with Diffusion Pharmaceuticals (NASDAQ: DFFN), creating a late-stage oncology-focused biotech company. As CEO at BioSante Pharmaceuticals, Inc., Mr. Simes helped secure significant funding through various financing transactions, acquisitions, and license arrangements. BioSante was later acquired by ANI Pharmaceuticals Inc (NASDAQ: ANIP). At Unimed Pharmaceuticals, Inc., a subsidiary of AbbVie Inc. (NASDAQ: ABBV), Mr. Simes built, developed, and successfully led research and development, finance, sales, and commercial activities, significantly expanding the product portfolio and increasing stockholder value.”
From your post, “Reverse stock splits don't affect the number of authorized shares, but a forward stock split issues new stock from the company's authorized shares.”
Speaking of Reverse and not Forward, when an R/S occurs and the authorized shares remain the same. What’s the math?
For instance, a 5 to 1 R/S.
We have about 800 million out. And 1.35 Billion authorized.
So theoretically, if our 800 million outstanding gets reversed, we end up with about 160 million outstanding, correct? At the same time, our shareholders authorized count remains at 1.35 billion.
IF we can sell all of those 1.2 billion remaining authorized shares at a X5 higher price than that would rock. The discussion I’m asking about is the in between part.
IF my example, (again, not saying it’s at all in the offing) is worthy of discussion, what might the engineering, timing, math, effect on my shares be? I’m hoping this guy both knows and has my best interest in mind.
“Stephen M. Simes
Director
Mr. Simes is an accomplished public company CEO who led a number of biopharmaceutical companies during his over 40 year career in the industry. He has extensive experience developing and implementing corporate strategies, establishing growth metrics, driving performance, and meeting growth objectives through organic expansion, acquisitions, and partnerships. When CEO at RestorGenex Corporation, Mr. Simes built a successful senior executive leadership team that delivered significant therapeutic products and stockholder value. He also negotiated the merger of RestorGenex with Diffusion Pharmaceuticals (NASDAQ: DFFN), creating a late-stage oncology-focused biotech company. As CEO at BioSante Pharmaceuticals, Inc., Mr. Simes helped secure significant funding through various financing transactions, acquisitions, and license arrangements. BioSante was later acquired by ANI Pharmaceuticals Inc (NASDAQ: ANIP). At Unimed Pharmaceuticals, Inc., a subsidiary of AbbVie Inc. (NASDAQ: ABBV), Mr. Simes built, developed, and successfully led research and development, finance, sales, and commercial activities, significantly expanding the product portfolio and increasing stockholder value.”
2
